GlassScriptPhysician profile
Phi T Huynh
NPI 1598742413
$11,674.93
in general payments reported to CMS, 2019-2025
26 companies · $1,884 in 2025
The $1,884 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,359 · 2020: $2,432 · 2021: $1,201 · 2022: $1,534 · 2023: $1,074 · 2024: $2,191 · 2025: $1,884.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,149.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $2,929.35 | 2019-2025 | Vemlidy |
| Astrazeneca Pharmaceuticals LP | $2,125.63 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $2,038.73 | 2019-2025 | Evenity, Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $721.06 | 2021-2025 | |
| Lilly USA, LLC | $684.32 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $546.08 | 2020-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $419.41 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Novo Nordisk INC | $368.32 | 2021-2025 | Rybelsus, Ozempic |
| Amarin Pharma, INC. | $366.96 | 2020-2023 | |
| Redhill Biopharma INC. | $273.15 | 2020-2025 | Talicia, Aemcolo, Movantik |
| Aimmune Therapeutics, INC. | $200.76 | 2024-2025 | Zenpep |
| Boehringer Ingelheim Pharmaceuticals, INC. | $194.80 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $189.07 | 2024-2025 | Voquezna |
| Scilex Pharmaceuticals INC. | $136.03 | 2024 | |
| Leo Pharma INC. | $121.15 | 2024 | Adbry |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $117.52 | 2024 | Rexulti |
| Pfizer INC. | $45.15 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.89 | 2023 | Xifaxan, Trulance |
| Teva Pharmaceuticals USA, INC. | $26.18 | 2019-2020 | |
| Genentech USA, INC. | $24.63 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $22.15 | 2021 | |
| Janssen Pharmaceuticals, INC | $21.15 | 2021 | |
| Paratek Pharmaceuticals, INC. | $20.16 | 2023 | Nuzyra |
| Kowa Pharmaceuticals America, INC. | $19.65 | 2023 | Seglentis, Livalo |
| Recordati_rare_diseases_inc. | $16.57 | 2025 | Isturisa |
| Optinose US, INC. | $15.06 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phi Huynh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.